MAOB as a Radioligand Therapy Target
MAOB, monoamine oxidase B, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, MAOB staining is highest in kidney cancer (100% of samples positive), prostate cancer (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is MAOB a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
MAOB expression in cancer
Protein expression of MAOB across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 1.00 | High | 100% |
| Prostate Cancer | 1.00 | High | 100% |
| Bladder Cancer | 0.94 | High | 100% |
| Pancreatic Cancer | 0.94 | High | 100% |
| Breast Cancer | 0.92 | High | 100% |
| Thyroid Cancer | 0.92 | High | 100% |
| Neuroendocrine Tumors | 0.92 | High | 100% |
| Gastric Cancer | 0.91 | High | 100% |
| Cervical Cancer | 0.90 | High | 100% |
| Liver Cancer | 0.89 | High | 100% |
| Colorectal Cancer | 0.86 | High | 100% |
| Glioma | 0.85 | High | 100% |
| Endometrial Cancer | 0.79 | High | 100% |
| Lung Cancer | 0.72 | High | 100% |
| Ovarian Cancer | 0.61 | High | 100% |
| Head and Neck Cancer | 0.58 | High | 100% |
| Skin Cancer | 0.50 | Medium | 100% |
| Lymphoma | 0.47 | Medium | 100% |
| Melanoma | 0.42 | Medium | 100% |
| Testicular Cancer | 0.36 | Medium | 100% |
Is MAOB internalized?
Nuclens has not yet extracted internalization evidence for MAOB. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
MAOB clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for MAOB yet. Search ClinicalTrials.gov for MAOB trials.
MAOB normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See MAOB in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
MAOB gene essentiality (DepMap)
CRISPR knockout effect across 1251 cancer cell lines: 0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how MAOB ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.